ID
115
Cancer Name
Triple-Negative Breast Cancer (TNBC)
Main Grouping
Endocrine/Reproductive
Organ System
Breast (Mammary Gland)
Cell Origin
Breast epithelial cells (mammary ductal/lobular epithelium)
Pathways Affected
Triple-negative breast cancer involves a pathway landscape dominated by TP53 pathway disruption (~80-85%), BRCA1/homologous recombination deficiency (~35-50%), PTEN-null/PI3K/AKT/mTOR activation (~50-65%), EGFR/MAPK/ERK signaling (~57-70% EGFR overexpression), IGF1R/PI3K/AKT-driven EMT and metastasis, MYC-driven metabolic reprogramming (~40% MYC amplification), and the androgen receptor signaling in the LAR subtype (~20-30%).
The TP53/p53 pathway is the most frequently disrupted pathway in TNBC: TP53 mutations in approximately 80-85% of TNBC — the single highest TP53 mutation frequency among all breast cancer subtypes (versus ~30% in ER+ and ~70% in HER2+ breast cancer); TNBC TP53 mutations are predominantly gain-of-function missense mutations (R175H, R248W, R273H, R248Q, G245S) creating oncogenic mutant p53 proteins that actively promote invasion, migration, angiogenesis, metabolic reprogramming, and resistance to DNA damage responses; mutant p53 promotes EGFR trafficking and surface expression by binding and inhibiting the recycling endosome machinery — amplifying the EGFR overexpression already present in TNBC; mutant p53 cooperates with NF-kB to transcriptionally activate pro-metastatic gene programs (MMP-13, IL-8, VEGF) in TNBC cells; quercetin was confirmed to inhibit viability of all five TNBC cell lines (MDA-MB-231, MDA-MB-468, MDA-MB-436, BT-20, BT-549) by MTT assay (PMC11626283) — including TP53-mutant cell lines; quercetin also activates p21/CDKN1A and promotes p53-independent apoptosis in TP53-mutant TNBC cell models; curcumin induces DNA damage and apoptosis in TNBC cell lines while modulating BRCA1 protein expression confirmed (PMC2756684).
The BRCA1/homologous recombination deficiency (HRD)/DNA damage response pathway is uniquely critical to TNBC biology: BRCA1 protein deficiency (through germline BRCA1 mutations ~10-20%, somatic BRCA1 promoter hypermethylation ~25-30%, BRCA1 protein dysfunction through multiple mechanisms) creates HRD in approximately 35-50% of TNBC; BRCA1 normally acts as a tumor suppressor through multiple mechanisms: participating in homologous recombination for double-strand break repair; activating ATM/ATR-mediated checkpoint kinase signaling; and maintaining chromosomal stability through centrosome regulation; in HRD TNBC, the inability to repair DNA double-strand breaks through HR creates dependence on alternative DNA repair pathways (NHEJ, PARP1-mediated); quercetin and curcumin were confirmed to dose-dependently upregulate BRCA1 expression in TNBC cell lines — both quercetin and curcumin enhanced BRCA1 promoter histone acetylation confirmed; curcumin was confirmed to induce DNA damage and apoptosis in TNBC cell lines while modulating BRCA1 protein (PMC2756684); quercetin was confirmed to inhibit BRCA1-knockdown-induced cell survival and migration confirmed (PubMed30478904).
The IGF1R/PI3K/AKT/mTOR/MAPK pathway is the primary proliferative survival axis in TNBC: PTEN loss (~35%) and PIK3CA mutations (~7-10%) both activate PI3K/AKT/mTOR; IGF1R overexpression drives PI3K/AKT and MAPK/ERK signaling in TNBC — quercetin was confirmed to inhibit IGF1R activation and downstream Akt and Erk1/2 dose-dependently in MDA-MB-231 TNBC cells by Western blot confirmed (PMC9261845); EGFR overexpression/amplification (~57-70%) adds parallel MAPK/ERK and PI3K/AKT activation; MYC amplification (~40%) drives downstream metabolic reprogramming including glutamine addiction (SLC1A5/GLS upregulation), ribosome biogenesis, and nucleotide synthesis.
Description
Triple-negative breast cancer (TNBC) is defined by the simultaneous absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 overexpression/amplification, representing approximately 10 to 15 percent of all invasive breast cancers. In the United States, approximately 30,000 to 35,000 new cases of TNBC are diagnosed annually — approximately 10-15% of the ~300,000+ annual invasive breast cancer diagnoses. Globally, the annual incidence of TNBC is estimated at approximately 170,000 to 250,000 new cases. TNBC has a disproportionate impact on younger women — the median age at diagnosis is approximately 40 to 50 years, significantly younger than the median age (~61 years) for ER+ breast cancer. TNBC disproportionately affects Black/African American women who have approximately a 2-fold higher incidence and worse outcomes compared to white women, reflecting both biological differences (higher BRCA1 mutation prevalence, higher frequency of basal-like molecular subtype) and socioeconomic disparities.
TNBC is the most biologically aggressive subtype of invasive breast cancer: it has the highest proliferative rate (Ki-67 typically >30-50%), shortest relapse-free interval after treatment, highest rates of visceral metastasis (lung, brain, liver), and worst 5-year OS among all breast cancer subtypes despite initial sensitivity to chemotherapy. The "triple-negative paradox" refers to the finding that TNBC initially responds to chemotherapy at higher rates than ER+ breast cancer — approximately 30-40% of TNBC patients achieve pathological complete response (pCR) to neoadjuvant chemotherapy — but patients who do not achieve pCR have dramatically worse outcomes than ER+ non-pCR patients (the residual disease in TNBC carries much higher risk of distant recurrence).
The molecular pathogenesis of TNBC is anchored by: TP53 mutations (~80-85% — the defining molecular feature distinguishing TNBC from ER+ breast cancer); BRCA1 germline and somatic deficiency (~35-50% through germline BRCA1 mutations plus somatic BRCA1 promoter methylation) creating homologous recombination deficiency (HRD) and "BRCAness"; PTEN-null/PI3K/AKT activation (~50-65%); EGFR overexpression/amplification (~57-70%); MYC amplification (~40%); and a high genomic instability landscape with extensive chromosomal copy number alterations and structural rearrangements.
Published laboratory research confirms quercetin from onions significantly inhibited viability of all five TNBC cell lines (MDA-MB-231, MDA-MB-468, MDA-MB-436, BT-20, BT-549) confirmed by MTT assay — IC50 values 15.3-55.2 µM (PMC11626283); and in MDA-MB-231 TNBC cells quercetin inhibited IGF1R activation and downstream Akt and Erk1/2 dose-dependently confirmed; suppressed metastatic phenotype and EMT of MDA-MB-231 cells confirmed; inhibited Snail and Slug EMT transcription factors confirmed (PMC9261845) — directly targeting the IGF1R/PI3K/AKT, MAPK/ERK, and EMT programs that define TNBC aggressiveness.
Plant-Based Description
Whole-food plant-based dietary patterns provide phytochemicals with confirmed activity directly in TNBC cell lines. Quercetin from onions and kale was confirmed to significantly inhibit viability of all five TNBC cell lines (MDA-MB-231, MDA-MB-468, MDA-MB-436, BT-20, BT-549) by MTT assay — IC50 values 15.3-55.2 µM confirmed (PMC11626283); in MDA-MB-231 TNBC cells, quercetin inhibited IGF1R activation and downstream Akt and Erk1/2 dose-dependently confirmed; suppressed metastatic phenotype and EMT confirmed; inhibited Snail and Slug EMT transcription factors confirmed; increased IGFBP3 secretion confirmed (PMC9261845); curcumin from turmeric was confirmed to induce DNA damage and apoptosis in TNBC cell lines MDA-MB-468, HCC1937, and HCC1806; modulate BRCA1 protein expression confirmed; promote BRCA1 histone acetylation confirmed (PMC2756684); additionally quercetin and curcumin together were confirmed to synergistically enhance BRCA1 expression in TNBC cell lines confirmed; inhibit TNBC cell survival and migration synergistically confirmed (PubMed30478904); sulforaphane activates Nrf2 and induces apoptosis in TNBC cell models; EGCG inhibits EGFR, PI3K/AKT, and MYC in TNBC cell models.
Plant Chemistry Detail
Quercetin from onions, kale, and apples has confirmed direct activity against all five TNBC cell lines in a published study (PMC11626283 — "Quercetin suppresses cell viability in triple-negative breast cancer by targeting ORM2") using TNBC cell lines MDA-MB-231, MDA-MB-468, MDA-MB-436, BT-20, and BT-549. In this confirmed study: quercetin significantly inhibited the viability of all five TNBC cell lines confirmed by MTT assay; IC50 values ranged from 15.3 µM to 55.2 µM across TNBC cell lines; normal non-tumorigenic breast epithelial cell lines MCF-10A and MCF-12A were also included as controls; quercetin targeted ORM2 (orosomucoid 2 / alpha-1-acid glycoprotein 2) — a secreted protein overexpressed in TNBC that promotes TNBC cell survival confirmed; quercetin reduced ORM2 expression in TNBC cells confirmed.
In a second confirmed study (PMC9261845 — "Quercetin blocks the aggressive phenotype of triple-negative breast cancer by inhibiting IGF1/IGF1R-mediated EMT program") using human MDA-MB-231 TNBC cells: quercetin inhibited the activation of IGF1R (insulin-like growth factor-1 receptor — overexpressed in TNBC driving PI3K/AKT and MAPK/ERK proliferative signaling) dose-dependently confirmed by Western blot; downstream kinases Akt and Erk1/2 phosphorylation significantly reduced confirmed — directly targeting the PTEN-null/PI3K/AKT (~50-65% of TNBC) and MAPK/ERK pathways in MDA-MB-231 TNBC cells; quercetin markedly suppressed the metastatic phenotype and EMT of MDA-MB-231 TNBC cells confirmed — TNBC is the breast cancer subtype with the highest rate of EMT-driven visceral metastasis (lung, brain, liver); EMT transcription factors Snail and Slug protein expression significantly inhibited confirmed by Western blot; quercetin increased IGFBP3 (IGF binding protein 3) secretion in MDA-MB-231 conditioned medium confirmed — reducing the autocrine/paracrine IGF1 loop; quercetin reduced IGF1 secretion confirmed.
Curcumin from turmeric was confirmed to induce apoptosis in TNBC cell lines MDA-MB-468, HCC1937, and HCC1806 but not in non-transformed MCF12A mammary epithelial cells confirmed — demonstrating cancer-selective apoptosis (PMC2756684); curcumin promoted phosphorylation, total expression, and cytoplasmic retention of BRCA1 protein in TNBC cells confirmed — BRCA1 cytoplasmic retention prevents BRCA1 from repairing DNA damage creating DNA damage-induced apoptosis; curcumin induced DNA damage confirmed. Quercetin and curcumin together dose-dependently enhanced BRCA1 expression in TNBC cell lines confirmed; synergistic action on BRCA1 promoter histone acetylation confirmed; synergistic inhibition of TNBC cell survival and migration confirmed (PubMed30478904) — both targeting the BRCA1 deficiency pathology that defines ~35-50% of TNBC. EGCG from green tea inhibits EGFR kinase and PI3K/AKT in TNBC cell models targeting EGFR overexpression (~57-70%) and PTEN-null PI3K/AKT activation in TNBC. Sulforaphane from cruciferous vegetables activates Nrf2/ARE and induces apoptosis in TNBC cell models; induces p21/CDKN1A targeting the high-proliferative TNBC cell cycle. Apigenin inhibits STAT3 and PI3K/AKT in TNBC cell models.
Nutritional Focus
Nutritional focus in TNBC targets the defining molecular drivers — TP53 mutations (~80-85%), BRCA1 deficiency (~35-50%), PTEN-null/PI3K/AKT activation (~50-65%), EGFR overexpression (~57-70%), and MYC amplification (~40%). Quercetin from onions confirmed to significantly inhibit viability of all five TNBC cell lines (MDA-MB-231, MDA-MB-468, MDA-MB-436, BT-20, BT-549) by MTT assay confirmed — IC50 15.3-55.2 µM (PMC11626283); quercetin inhibiting IGF1R activation and downstream Akt and Erk1/2 dose-dependently in MDA-MB-231 TNBC cells confirmed; suppressing metastatic phenotype and EMT confirmed; inhibiting Snail/Slug EMT transcription factors confirmed; increasing IGFBP3/reducing IGF1 autocrine loop confirmed (PMC9261845) — directly targeting PI3K/AKT (~50-65%), MAPK/ERK, and EMT-driven visceral metastasis biology in TNBC; curcumin from turmeric confirmed to induce DNA damage and apoptosis in TNBC cell lines MDA-MB-468, HCC1937, HCC1806 but not normal breast epithelial cells; BRCA1 protein modulated confirmed; BRCA1 cytoplasmic retention confirmed (PMC2756684) — targeting the BRCA1 deficiency in ~35-50% of TNBC; quercetin and curcumin synergistically confirmed to upregulate BRCA1 expression and inhibit TNBC cell survival and migration through BRCA1 promoter histone acetylation confirmed (PubMed30478904); EGCG from green tea inhibiting EGFR kinase and PI3K/AKT targeting EGFR overexpression (~57-70%) and PTEN-null PI3K/AKT activation in TNBC; sulforaphane activating Nrf2/ARE and inducing apoptosis in TNBC cell models; inducing p21/CDKN1A targeting the high-proliferative TP53-mutant TNBC cell cycle; dietary fiber producing butyrate/SCFAs inhibiting HDAC targeting BRCA1 promoter histone acetylation in sporadic BRCA1-methylated TNBC.
Research Notes
TNBC epidemiology: ~10-15% of all invasive breast cancer; ~30,000-35,000 new US cases/year; globally ~170,000-250,000 new cases/year; female predominance (exclusively in women); median age diagnosis ~40-50 years (younger than ER+ median ~61 years); Black/African American women ~2x higher incidence and worse outcomes; highest breast cancer subtype Ki-67 (>30-50%); preferential metastasis to lung, brain, liver (visceral — vs. bone in ER+); brain metastasis ~25-46% during disease course; 5-year OS: stage I ~91%; II ~65%; III ~46%; IV ~11%; worst prognosis among breast cancer subtypes. IHC definition: ER <1%, PR <1%, HER2 0/1+ (or 2+ FISH non-amplified). Molecular: TP53 mutations ~80-85% (highest frequency of any breast cancer subtype — predominantly gain-of-function missense mutations); PIK3CA ~7-10%; PTEN loss ~35% (deletion/mutation/promoter methylation); BRCA1 germline ~10-20% of TNBC; somatic BRCA1 promoter hypermethylation ~25-30% additional sporadic TNBC; BRCA2 germline ~5%; HRD "BRCAness" ~35-50%; EGFR overexpression/amplification ~57-70%; MYC amplification ~40%; RB1 loss ~20-25%; AR positive ~20-30% (LAR subtype); PD-L1 positive ~20-40% (IM subtype). Lehmann 2016 six subtypes: BL1 (cell cycle/DNA damage — highest pCR rate); BL2 (growth factor signaling enriched); M (mesenchymal/EMT); MSL (claudin-low/stem-like); IM (immune-enriched); LAR (AR+, PIK3CA-enriched). Quercetin in TNBC: PMC11626283 — all 5 TNBC cell lines viability inhibited MTT; IC50 15.3-55.2 µM; non-tumorigenic MCF-10A/MCF-12A included; ORM2 targeted. PMC9261845 — MDA-MB-231 IGF1R inhibited dose-dependent; Akt/Erk1/2 reduced Western blot; Snail/Slug reduced; IGFBP3 increased; IGF1 reduced; EMT/metastasis suppressed. Curcumin TNBC: PMC2756684 — apoptosis in MDA-MB-468/HCC1937/HCC1806 confirmed; BRCA1 modulated; DNA damage induced; normal cells sparing. PubMed30478904 — quercetin+curcumin synergistic BRCA1 upregulation; BRCA1 promoter histone acetylation; cell survival/migration inhibited in TNBC lines.
Notes Visibility
Key Foods
Turmeric,Broccoli,Kale,Spinach,Brussels Sprouts,Cauliflower,Garlic,Yellow Onion,Carrot,Tomato,Beetroot,Cabbage,Blueberry,Pomegranate,Grape,Raspberry,Apple,Orange,Lemon,Soybeans,Edamame,Green Lentils,Black Beans,Chickpeas,Brown Rice,Quinoa,Oats,Wild Rice,Black Rice,Walnut,Almond,Brazil Nut,Flaxseed,Pumpkin Seeds,Chia Seeds,Sesame Seeds,Hemp Seeds,Shiitake,Maitake,Lions Mane,Cremini,Portobello,Green Tea,Ginger,Black Pepper,Garlic Powder,Parsley,Rosemary,Oregano, Celery, Fennel, Leek,Avocado,Artichoke,Endive,Radish,Parsnip,Radicchio,Fig,Tangerine,Dragon Fruit Red, Red Onion
Linked Nutrients
vitamin-c,vitamin-e,vitamin-a,vitamin-b9,vitamin-b6,selenium,zinc,magnesium,calcium,potassium,iron,quercetin,curcumin,egcg,sulforaphane,beta-carotene,anthocyanins,dietary-fiber,l-theanine,allicin
